DES PLAINES, Ill., June 28 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration to market a new, sensitive molecular diagnostic test and instrument to simultaneously detect two of the nation's most prevalent sexually transmitted diseases (STDs), gonorrhea and chlamydia, including a new variant strain of chlamydia recently discovered in Sweden. Abbott received independent 510(k) clearances for both the Abbott RealTime Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) assay and the Abbott m2000 System.
Survey: Many Young Women Lack Accurate Information about STDs
Dr. Heather Royer, a University of Wisconsin-Madison School of Nursing researcher, surveyed 302 women, 18 to 24 years old, about their beliefs about STD testing.
Don't Let STD's Prevent You From Becoming a Mother ' Rid it Before it Ruins Your Infertility
A lot of people have no idea that fertility can be ruin by sexually transmitted diseases or STD In fact a large number of women in the United States alone have infertility problems because of this
